Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | STING1 | Q86WV6 | 9/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30712246 | 0.93 | POLB (0.58) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL29546691 | 0.92 | POLB (0.57) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL3503649 | 0.91 | POLB (0.56) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL3501824 | 0.90 | POLB (0.55) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL28094790 | 0.87 | POLB (0.59) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL3779342 | 0.85 | POLB (0.55) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL6914307 | 0.84 | POLB (0.59) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL13252942 | 0.84 | POLB (0.59) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL10015775 | 0.84 | POLB (0.59) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL5418169 | 0.83 | POLB (0.51) | POLBSTING1PDE3BPDE3APNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022242-A1 | NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS | Katholieke Universiteit Leuven, KU LEUVEN R&D (BE) | 2017-01-26 | — | — | US | claimed |
| WO-2015158913-A1 | NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-10-22 | — | — | WO | claimed |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | INSIGNIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| EP-3678648-B1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS INC (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-114729369-A | Minimal mRNA and uses thereof | 苏黎世大学 | 2022-07-08 | — | — | CN | disclosed |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS INC (US) | 2022-06-23 | — | — | US | disclosed |
| US-11213496-B2 | Methods of using dipivefrin | Insignis Therapeutics, Inc. (US) | 2022-01-04 | — | — | US | disclosed |
| EP-3678648-A1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS, INC. (US) | 2020-07-15 | — | — | EP | disclosed |
| WO-2019051387-A1 | METHODS OF USING DIPIVEFRIN | ZHANG MINGBAO (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20190076378-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2019-03-14 | — | — | US | disclosed |
| WO-2004047736-A2 | MODULATION OF BCL2-ASSOCIATED ATHANOGENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048531-A2 | MODULATION OF DEATH-ASSOCIATED PROTEIN KINASE 1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004047741-A2 | MODULATION OF IAP-LIKE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048523-A2 | MODULATION OF KU86 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048524-A2 | MODULATION OF STAT2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004046326-A2 | MODULATION OF INTERLEUKIN 22 RECEPTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004045527-A2 | MODULATION OF NIMA-RELATED KINASE 6 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004043391-A2 | MODULATION OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 11 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004044141-A2 | CONJUGATED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190076378-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | POLB 4023/4885STING1 572/4885PDE3B 1151/4885 |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | POLB 4023/4885STING1 572/4885PDE3B 1151/4885 |
| US-20170022242-A1 | NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS | PNP, NTPCR, ENTPD5 | POLB 237/4885STING1 125/4885PDE3B 2300/4885 |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | POLB 4023/4885STING1 572/4885PDE3B 1151/4885 |
| US-11213496-B2 | Methods of using dipivefrin | QDPR, DNPEP, DPEP1 | POLB 4023/4885STING1 572/4885PDE3B 1151/4885 |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | ADRB3, ADRB2, ADRB1 | POLB 4473/4885STING1 942/4885PDE3B 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.